AR077858A1 - Uso de la 4-aminopiridina para mejorar el deterioro cognitivo en pacientes con desmielinizacion y otros estados del sistema nervioso - Google Patents

Uso de la 4-aminopiridina para mejorar el deterioro cognitivo en pacientes con desmielinizacion y otros estados del sistema nervioso

Info

Publication number
AR077858A1
AR077858A1 ARP100102953A ARP100102953A AR077858A1 AR 077858 A1 AR077858 A1 AR 077858A1 AR P100102953 A ARP100102953 A AR P100102953A AR P100102953 A ARP100102953 A AR P100102953A AR 077858 A1 AR077858 A1 AR 077858A1
Authority
AR
Argentina
Prior art keywords
patients
demielinization
aminopiridine
states
nervous system
Prior art date
Application number
ARP100102953A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Blight
Thomas C Wessel
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of AR077858A1 publication Critical patent/AR077858A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP100102953A 2009-08-11 2010-08-11 Uso de la 4-aminopiridina para mejorar el deterioro cognitivo en pacientes con desmielinizacion y otros estados del sistema nervioso AR077858A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23306909P 2009-08-11 2009-08-11
US23307709P 2009-08-11 2009-08-11
US23987709P 2009-09-04 2009-09-04

Publications (1)

Publication Number Publication Date
AR077858A1 true AR077858A1 (es) 2011-09-28

Family

ID=43586462

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102953A AR077858A1 (es) 2009-08-11 2010-08-11 Uso de la 4-aminopiridina para mejorar el deterioro cognitivo en pacientes con desmielinizacion y otros estados del sistema nervioso

Country Status (17)

Country Link
US (8) US20130053420A1 (enExample)
EP (1) EP2464229B1 (enExample)
JP (2) JP6137833B2 (enExample)
KR (2) KR20120050473A (enExample)
CN (1) CN102143687B (enExample)
AR (1) AR077858A1 (enExample)
AU (1) AU2010282509B2 (enExample)
BR (1) BRPI1003991A2 (enExample)
CA (1) CA2770698C (enExample)
ES (1) ES2563751T3 (enExample)
JO (1) JO3348B1 (enExample)
MX (1) MX2012001814A (enExample)
RU (1) RU2563821C2 (enExample)
TW (2) TW201613585A (enExample)
UY (1) UY32837A (enExample)
WO (1) WO2011019845A1 (enExample)
ZA (1) ZA201201001B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20130184316A1 (en) * 2010-07-15 2013-07-18 Andrew Hornstein Methods for diagnosing and treating concussive disorders
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
US10793893B2 (en) 2011-06-30 2020-10-06 Serb Sa Methods of administering 3,4-diaminopyridine
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
CA2909527A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
DE102014221687B4 (de) * 2014-10-24 2019-07-04 Danfoss Silicon Power Gmbh Leistungshalbleitermodul mit kurzschluss-ausfallmodus
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
AU2002250307A1 (en) * 2001-03-14 2002-09-24 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Improving postsynaptic response by a combination of 4-minopyridine and agonist
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Also Published As

Publication number Publication date
CN102143687A (zh) 2011-08-03
EP2464229A4 (en) 2013-02-13
CA2770698A1 (en) 2011-02-17
JP2016074728A (ja) 2016-05-12
US20130053420A1 (en) 2013-02-28
JP2013501805A (ja) 2013-01-17
US20190015399A1 (en) 2019-01-17
KR20170128633A (ko) 2017-11-22
RU2563821C2 (ru) 2015-09-20
EP2464229A1 (en) 2012-06-20
RU2012108656A (ru) 2013-09-20
US20170281608A1 (en) 2017-10-05
UY32837A (es) 2011-03-31
KR20120050473A (ko) 2012-05-18
US20200113882A1 (en) 2020-04-16
ZA201201001B (en) 2014-10-29
AU2010282509A1 (en) 2012-03-01
MX2012001814A (es) 2012-06-01
BRPI1003991A2 (pt) 2015-09-15
TW201613585A (en) 2016-04-16
TWI549678B (zh) 2016-09-21
HK1173911A1 (zh) 2013-05-31
JO3348B1 (ar) 2019-03-13
ES2563751T3 (es) 2016-03-16
US20170056385A1 (en) 2017-03-02
TW201110967A (en) 2011-04-01
WO2011019845A1 (en) 2011-02-17
US20180147193A1 (en) 2018-05-31
JP6137833B2 (ja) 2017-05-31
CN102143687B (zh) 2015-11-25
AU2010282509B2 (en) 2015-07-30
US20160213661A1 (en) 2016-07-28
US20190247379A1 (en) 2019-08-15
CA2770698C (en) 2018-01-30
EP2464229B1 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
EA201890852A1 (ru) Соли валбеназина и их полиморфы
UY32837A (es) Uso de la 4-aminopiridina para mejorar el deterioro cognitivo en pacientes con desmielinizacion y otros estados del sistema nervioso
CL2019003650A1 (es) Imidazopirimidinas diazabicíclicas sustituidas y su uso para el tratamiento de trastornos respiratorios.
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
CL2012001605A1 (es) Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño.
EA201590663A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
PH12013502382B1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
WO2013184876A8 (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
CL2012002487A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina, inhibidores de pde10; composicion farmacéutica que los comprende; proceso para preparar la composicion farmaceutica; utiles para el tratamiento de enfermedades neurológicas, psiquiátricas o metabólicas tales como esquizofrenia, parkinson y diabetes, entre otras.
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
UY32879A (es) Tratamiento con fampridina de liberación sostenida en pacientes con esclerosis multiple
WO2014082738A8 (en) Heteroquinoline-3-carboxamides as kcnq2/3 modulators
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure